2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow MF: new trials by email Literature Review of MF trials Research Report on MF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis Flonoltinib 75mg, Ruxolitinib Phosphate - MF | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-02-13 | 2026-08-13 |
| Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Navtemadlin, Navtemadlin placebo, Ruxolitinib - Myelofibrosis, Post-PV MF | Phase 3 | Recruiting | Kartos Therapeutics, Inc. | 600 | 2024-06-03 | 2025-09-25 |
Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Myeloproliferative Disorders (1)
ruxolitinib (2) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1)
Chengdu Zenitar Biomedical Technology Co., Ltd (1) · Kartos Therapeutics, Inc. (1)
Australia (1) · Austria (1) · Belgium (1) · China (1) · Croatia (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Portugal (1) · Romania (1)
Miao Jia, Doctor (1) · Niu Ting, Doctor (1) · Xiao Zhijian, Doctor (1)